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http://dx.doi.org/10.1016/j.gmbhs.20Abstract Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear
receptors that mediate numerous crucial physiological processes, including glucose and lipid
metabolism, energy homeostasis, inflammation, cell proliferation, and differentiation. There-
fore, targeting of PPARs for metabolic diseases, cardiovascular diseases, polycystic ovary syn-
drome, and cancer therapies is intensive. Over the last decade, studies on PPARs have shed
light on their functional roles in the female reproductive system, including the hypothala-
musepituitaryegonad axis, placental development, and maternal-infant interactions. In this
review we summarize PPAR genomic organization, molecular functions, and expression pat-
terns, as well as insights from knockout mice and PPAR involvement in biological processes,
with a focus on their novel role in the pituitary gland in female reproduction.
Copyright ª 2013, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Biomedical Science, National
, 80424 Kaohsiung, Taiwan.
.edu.tw (Y.-L. Shiue).
an Genomic Medicine and Bioma
13.04.008Introduction
Peroxisome proliferator-activated receptors (PPARs) are
nuclear receptors that are predominantly known for their
involvement in fatty acid and lipoprotein metabolism,
glucose homeostasis, cellular proliferation and differenti-
ation, and the immune response.1 Accordingly, PPARs arerker Society. Published by Elsevier Taiwan LLC. All rights reserved.
2 Y.-L. Shiue et al.important targets in the treatment of metabolic disorders
such as type 2 diabetes mellitus and are of interest in
relation to chronic inflammatory diseases. Recent studies
further identified novel functions of PPARs in blood pres-
sure regulation,2 neuroinflammation,3 neuroprotection,4
and inflammatory pain reduction.5
The abundant pleiotropic actions of PPARs suggest that
PPAR agonists have enormous therapeutic potential.6
Ongoing research indicates that modulation of PPAR activ-
ity might be an effective therapy for additional conditions
associated with the metabolic syndrome, including insulin
resistance, inflammation, obesity, hyperlipidemia, hyper-
tension, andheart disease.7e14Moreover, PPARs play a role in
the regulation of cancer cell growth,15,16 so specific PPAR
agonists might have different effects on cancer incidence.17
The impact of PPARs on female reproduction across
vertebrates has recently been highlighted. Regulatory roles
of PPARs in placental development during pregnancy,18,19
from gametogenesis to parturition,20,21 and in normal
ovarian function22 have been identified. We found that
PPARs are expressed in the pituitary gland and play a role in
the hypothalamusepituitaryegonad axis in female repro-
duction.23 Multifaceted roles of PPARs at the cellular and
whole organism levels have been reviewed elsewhere,6,24
so here we focus on their role in the pituitary gland in fe-
male reproduction according to recent findings.The PPAR superfamily
The nuclear receptor family of transcription factors is quite
large and can be categorized into three subgroups accord-
ing to specific ligand binding: (1) classic hormone receptors
(e.g., the glucocorticoid, estrogen, thyroid, retinoic acid,
and vitamin D receptors); (2) sensor receptors (e.g., PPARs,
liver X receptor, farnesol X receptor, and retinoid X re-
ceptor, RXR)25,26; and (3) orphan nuclear receptors (e.g.,
apolipoprotein A-I regulatory protein-1 and chicken oval-
bumin upstream promoter transcription factor). The PPARs
were originally named for their ability to induce hepatic
peroxisome proliferation in mice in response to xenobiotic
stimuli.27 The classic hormone receptors bind specific li-
gands with high affinity; by contrast, a broad range of
lipophilic molecules bind to the sensor receptors, generally
with low affinity compared to hormones that bind to the
classic hormone receptors.28
Across vertebrates, PPAR evolved into three paralogs:
PPAR-alpha (PPARA), PPAR-delta (PPARD, also known as
PPARb) and PPAR-gamma (PPARG).29 Although the genomic
organization of PPARs differs to some extent,30e32 each
specific PPAR shares high protein sequence homology
(Fig. 1A) across human, rat, mouse, and chicken species
(Fig. 1B). Human PPARA, PPARD, and PPARG are encoded by
three different genes. Alternative promoters give rise to two
major PPARG/Pparg isoforms, g1 and g2, in humans,15
mice,33 and rats.34 Studies at the protein level revealed
that the three human PPARs share 64% and 85% homology in
their ligand- and DNA-binding domains.15 As shown in Fig. 1C,
the peroxisome proliferator response element (PPRE) is the
DNA-binding sequence in PPARs. PPRE consists of a consensus
DNA hexamer (A/GGGTCA) arranged as either a single half-
site or, more often, as two tandem half-sites arranged asdirect, inverted (palindromic), or everted repeats.35,36 In
general, themajority of PPREs identified in genes responsive
to PPAR ligands have a direct repeat separated by one spacer
nucleotide structure (also knownas DR1), even though other,
more complex PPREs have been reported. PPARs only bind
DNA as heterodimers with RXR alpha (RXRA, a sensor recep-
tor) and cannot bind DNA as homodimers or monomers. DNA
interaction is greatly enhanced by the binding of ligands to
RXRA37 and to PPAR.38 The PPAReRXRA heterodimer is polar,
with PPAR occupying the 50 0 and RXRA the 30 position when
bound to the DR1/PPRE (Fig. 1C).PPAR molecular functions and expression
patterns
According to their secondary structure conservation and
Gene Ontology annotations,39 human PPAR paralogs are
involved in intersecting molecular functions that include
ligand binding,38,40,41 ligand-activated sequence-specific
DNA-binding RNA polymerase II transcription factor activ-
ity,40,41 lipid binding,41 protein binding,42,43 and sequence-
specific DNA-binding transcription factor activity41,44,45
(Fig. 2). According to the Expressed Sequence Tag database
(dbEST; NCBI, Bethesda, MD, USA) and many studies,31,32,46
human PPARA is highly expressed (50 per million ESTs) in
adrenal gland, intestine, kidney, liver, muscle (skeleton),
and nerve. PPARD is predominantly expressed in brain,
nerves, ovary, placenta, prostate, spleen, thymus, thyroid,
trachea, umbilical cord, and uterus. PPARG is highly
expressed in adipose tissue, bone, cervix, intestine, nerves,
and placenta. We and others recently found that PPARs are
expressed in early embryos, developing fetuses, and various
compartments of the reproductive system (hypothalamus,
pituitary gland, ovary, uterus, and testis) in many species,
including birds, fishes, andmammals such as rodents, cattle,
pigs, andhumans.22,23,47e50 Double immunostaining revealed
that every human pituitary secreting cell lineage [growth
hormone (GH), thyroid-stimulate hormone (TSH), follicle-
stimulating hormone (FSH), luteinizing hormone (LH), pro-
lactin (PRL), and adrenocorticotropic hormone (ATCH)] ex-
presses PPARG.51 Furthermore, pituitary gland PPAR
expression has been observed across several species,
including human, mouse, rat, sheep and chicken.23,47,50,52,53
The pituitary gland secretes nine hormones that regulate
homeostasis and PPARG protein is highly expressed in every
normal pituitary secreting cell lineage.51 Thus, PPARs might
be involved in specific molecular functions in this organ.PPARs are involved in overlapping and distinct
biological processes
Each PPAR is involved in both specific and inter-related
biological processes. For example, both PPARA and PPARD
participate in the intracellular receptor-mediated signaling
pathway.41 PPARA and PPARG negatively regulate choles-
terol storage and macrophage-derived foam cell differen-
tiation.54 PPARA also plays roles in negative regulation of
receptor biosynthesis, sequestering of triglycerides, and
RNA polymerase II promoter transcription.55 Both PPARD
and PPARG are involved in apoptosis.56,57 PPARG has been
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Figure 1 Peroxisome proliferator-activated receptors (PPARs) are highly conserved in vertebrates. (A) Functional domains of a
typical PPAR member. N, amino-terminus; C, carboxy-terminus. Domains A/B, activation function 1 (AF1; transactivation); domain
C, DNA-binding domain (DBD); domain D, flexible hinge region; domains E/F, ligand-binding domain (LBD) and activation function 2
(AF2) for transactivation, dimerization, and coactivator recruitment. Similar domain allocations are shown at the bottom for the
human and mouse forms. Feature annotations are based on the UniProt database (http://www.uniprot.org/). Alternative splicing
exists in both human PPARG and mouse Pparg genes: the first 30 amino acids are missing in isoform 1, but not isoform 2. (B)
Phylogenetic tree of PPARs in human (h), rat (r), mouse (m), and chicken (c) demonstrates that a specific PPAR (PPARA, PPARD, or
PPARG) is highly conserved across vertebrates compared to its corresponding paralogs; Xenopus PPARA served as the out-group. (C)
Typical PPAReretinoid X receptor alpha (RXRA) heterodimer complex.
PPARs in the pituitary gland in female reproduction 3implicated in the activation of cysteine-type endopeptidase
activity in apoptosis,57 cell maturation,58 cellular responses
to insulin stimulus, glucose homeostasis,40 lipoprotein
transport, low-density lipoprotein (LDL) particle receptor
biosynthesis, and monocyte differentiation.58Ligands for PPARs
The main natural ligands for PPARs are the intermediate
and end products of fatty acid and sterol metabolic
pathways, including fatty acid derivatives and eicosa-
noids.38 These small lipophilic molecules can freely parti-
tion into cells. PPARA is activated by a variety of long-
chain polyunsaturated fatty acids, including linoleic acid,
branched, conjugated, and oxidized fatty acids such as
phytanic acid, conjugated linolenic acid, and eicosanoidssuch as 8S-hydroxy-5Z,9E,11Z,14Z-eicosatetraenoic acid
and leukotriene B4.59e62 Prostaglandin D2 (PGD2) and PGJ2
are naturally occurring ligands for PPARs.63 The endoge-
nous PGD2 metabolite 15-deoxy-D12,14-prostaglandin J2
(15-d-PGJ2) is the most potent natural ligand of
PPARG.64,65 Intriguingly, two pathophysiological oxidized
metabolites of linoleic acid, 9-hydroxy and 13-hydroxy
octadecadienoic acid (9- and 13-HODE), which are pre-
sent in oxidized LDL, have been suggested as PPARG li-
gands.45,58 Linoleic acid, arachidonic acid (AA),
eicosapentaenoic acid, and prostaglandin A1 bind to
PPARD in the micromolar range.38,66
PPARs have a large ligand-binding pocket (1300 A˚),67 so
they are capable of binding to several structurally diverse
compounds, including industrial chemicals such as herbi-
cides and plasticizers, as well as pharmaceutical com-
pounds including hypolipidemic fibrates and antidiabetic
Figure 2 Molecular functions of human peroxisome proliferator-activated receptors (PPARs) according to in vivo or in vitro
evidence. All PPARs during drug binding, ligand-activated sequence-specific DNA-binding RNA polymerase II transcription factor
activity, and sequence-specific DNA-binding transcription factor activity. Protein binding function overlaps between PPARA and
PPARG. Some molecular functions have been found for PPARA, PPARD, and PPARG individually.38,40e45
4 Y.-L. Shiue et al.thiazolidinediones (TZDs; e.g., rosiglitazone, pioglitazone,
and troglitazone). Transactivation assays have revealed
that a variety of exogenous compounds selectively activate
PPAR paralogs; for example, WY-14643 binds to PPARA and
PPARG,31,68 clofibrate and eicosatetraenoic acid bind to
PPARA,69e71 and troglitazone, rosiglitazone, and pioglita-
zone bind to PPARG.69,70 The synthetic ligand fibrate (or
bezafibrate) is an agonist of all PPARs.72 In addition, PPARs
may modulate gene transcription by directly interfering
with other transcription factor pathways in a manner in-
dependent of DNA binding.69,73Insights from Ppars knockout mice
Knockout of Ppar genes in mouse or rat models has provided
evidence to support the pleiotropic effects of the Ppar gene
family. For example, Ppara deficiency causes inflammatory
responses74; abnormal fatty acid metabolism75e77; resis-
tance to peroxisome proliferation76; a lack of hepatic cell
proliferation in response to the agonist WY-1464375; a lack
of Ppara-induced genes involved in fatty acid metabolism76;
an increase in sensitivity to cellular oxidative stress78; a
decrease in basal levels of mitochondrial fatty-acid-
catabolizing enzymes and mediation of inducible mito-
chondrial and peroxisomal fatty acid beta-oxidation79;
progressive dyslipidemia in sexually dimorphic obesity and
steatosis80; and increases in maternal abortion, neonatal
mortality, and T cell differentiation.81
Lack of Ppard in mice downregulates expression of
apolipoprotein C-II (Apoc2) and Apoc3, both of which arecomponents of very-low-density lipoprotein in the small
intestine involved in triglyceride catabolism.82 During early
tumorigenesis, Ppard-deficient mice are prone to colon
polyps in adenomatosis polyposis coli mutants or chemically
induced systems compared to wild-type counterparts.83
In vivo, Ppard mediates cyclin-dependent kinase inhibitor
1C (also known as p57) to inhibit cell proliferation and
tumor angiogenesis.84 Opsonins such as complement
component-1qb are suppressed in Pparde/e mice, which
results in impairment of apoptotic cell clearance and re-
ductions in anti-inflammatory cytokine production.85 Dele-
tion of Ppard results in frequent (>90%) midgestation
lethality due to defects of the placenta; surviving Pparde/e
mice exhibit a striking reduction in adiposity relative to
wild-type levels. Therefore, Ppard has an important role in
normal adipose development and lipid homeostasis.86
Deficiency of Pparg results in two independent lethal
phases, suggesting that Pparg is required for placental, car-
diac, and adipose tissue development. Notably, dependence
of the developing heart on a functional placenta was
observed.87 Viable Pparg-null mice generated via specific
and total epiblastic gene deletion demonstrated that this
placental defect is the unique cause of Pparge/e embryonic
lethality; however, vasculature defects were observed in
placentas on embryonic day 9.5.88 Conditional disruption of
Pparg inmurine peritonealmacrophages by ligand treatment
results in lower expression a series of Pparg-responsive
genes, indicating that Pparg plays a critical role in the
regulation of cholesterol homeostasis by controlling the
expression of a network of genes that mediate cholesterol
efflux from cells and its transport in plasma.89 Leptin-
PPARs in the pituitary gland in female reproduction 5deficient (Lepe/e) mice usually have severe obesity and a
fatty liver,whichcanbe remediedbyco-knockout ofPparg.90
Heterozygous loss of Pparg causes an increase in beta-
catenin levels and a greater incidence of colon cancer
when animals are treated with azoxymethane.91 Using Cre/
loxP technology, the expression of Ppargwas disrupted in the
ovary, rendering one-third of females sterile and the
remaining females subfertile. Females that were subfertile
took longer to conceive and had smaller litters.92 Conditional
knockout of Pparg in pituitary gonadotrophs caused an in-
crease in blood LH levels in femalemice, a decrease in FSH in
male mice, and a fertility defect characterized by reduced
litter size.47 These data indicate that PPARs regulate normal
placental embryonic development and PPARG regulates
expression levels of gonadotropins (FSH and LH) in vivo.
PPARs and proper placenta development
In rat, mouse, cattle, and human species, PPARs are highly
expressed in various placental locations.19 Their predomi-
nant expression in trophoblasts suggest specific roles of
PPARs in trophoblast differentiation and functions. Studies
on cellular models revealed that human PPARA, PPARD,
and/or PPARG inhibit cell growth,93 which might be regu-
lated by suppression of 11-beta-dehydrogenase activity,94
stimulate the synthesis95 and secretion93 of chorionicgo-
nadotropin and trophoblast differentiation,95 increase free
fatty acids uptake,96 and inhibit cell invasion.97,98
Clinically, enhanced expression of PPARG and the pro-
liferative index protein Ki-67 in villous and extravillous
trophoblasts has been documented in missed abortion.99
Secreted by white adipocytes, LEP plays a major role in
the regulation of body weight through the LEP receptor. In
the placenta, LEP also has several endocrine functions and
is involved in the regulation of immune and inflammatory
responses, hematopoiesis, angiogenesis, and wound heal-
ing. Decreased LEP levels are associated with miscarriage
and LEP homeostasis is connected to PPARG via a negative
feedback loop.100 LEP-mediated secretion of proin-
flammatory cytokines such as interleukin 1 beta, inter-
leukin 6, tumor necrosis factor, and prostaglandin E2 is
inhibited by PPARG activation.101,102 Therefore, it has been
suggested that PPARs are key messengers responsible for
the translation of nutritional or metabolic stimuli into
changes in gene expression pathways with high spatial and
temporal specificity for placenta development.103,104
PPARs and the HPG axis in female reproduction
In vertebrates, reproduction is primarily controlled by the
HPG axis and this endocrine pathway is highly conserved in
jawed vertebrates (gnathostoma). The hypothalamic
neuroendocrine system, especially gonadotropin-releasing
hormone (GnRH), regulates the synthesis and release of
gonadotropins from the pituitary, and these in turn stimu-
late gonadal development, in particular via the induction of
sex steroid synthesis. Sex steroid feedback to the hypo-
thalamus and the pituitary regulates gonadotropin synthe-
sis and release.105
Once released into the bloodstream, gonadotropins
exert their biological activities via G-protein-coupledreceptors (GPCRs). The presence of FSH and LH from the
pituitary gland and of their corresponding FSHR and LHR
receptors in gonads is well documented in male and female
vertebrates. The primary function of the HPG axis is to
facilitate the production of germ cells and to coordinate
reproductive events in relation to body condition and
environment. In addition to its function in adult animals,
the HPG axis regulates the differentiation of sex-specific
phenotype during early development. In female mammals
an dbirds,106 FSH stimulates the maturation of ovarian fol-
licles and the LH surge causes release of an egg from
mature follicles. FSH, LH, and another hormone secreted by
the anterior pituitary, TSH, are heterodimeric glycoprotein
hormones consisting of a non-covalently linked common
glycoprotein hormone a-subunit (also known as CGA) and a
specific b-subunit (FSHB, LHB, or TSHB) that confer bio-
logical activity. In Chinese hamster ovary cells, LHB syn-
thesis has been identified as the critical step in LH
formation.107 Accordingly, LHB transcription and trans-
lation may play vital roles in LH synthesis and surges and
the consequent ovulation across vertebrates.
Over the past 10 years, a number of in vivo and in vitro
studies have strongly suggested that PPARs play significant
roles from gametogenesis to parturition, including gesta-
tion and the connection between mother and fetus.20 Fuel
sensors, such as glucose, insulin, and LEP, directly regulate
fertility at each level of the HPG axis,108 and it is proposed
that PPARG acts as a fuel sensor in reproductive compart-
ments to inform cells of the energy status. In this case,
PPARG may be a link between energy metabolism and
reproduction, as both are frequently associated with insulin
resistance in polycystic ovary syndrome (PCOS)109 and
gestational diabetes.110Hypothalamus
The rat hypothalamus expresses PPARG, which is activated
by its natural ligand 15-d-PGJ2 in cerebrospinal fluid to play
at least a partial role in antipyretic action.111 However,
PPARG was not detected in a hypothalamus extract from
sheep.52 The role of PPARs in reproduction remains elusive.
So far, studies on hypothalamic PPARs are limited.Pituitary gland
Across vertebrates, the pituitary gland regulates homeostasis
via the secretion of numerous hormones. In the anterior pi-
tuitary, GH,TSH, corticotropin, lactotrophin, FSH, and LHare
synthesized and secreted under the control of the hypothal-
amus. Hypothalamic hormones are secreted to the anterior
lobe via a special capillary system, the hypothal-
amicehypophyseal portal system. Another GPCR, GnRH re-
ceptor (GnRHR), is synthesized by gonadotrophs and
expressed on the surface of pituitary gonadotrope cells as
well as some other tissues.112 Following binding to GnRH,
GnRHRassociateswithGproteins thatactivateaphosphatidyl
inositolecalcium secondmessenger system.Activation of this
receptor ultimately causes the synthesis and release of FSH
and LH. Therefore, GnRH and GnRHR play a pivotal role in the
control of reproduction in vertebrates.
6 Y.-L. Shiue et al.Compared to mammals, the chicken serves as an excel-
lent model to observe ovulation in a noninvasive manner. We
found significantly elevated expression of hematopoietic
prostaglandin D synthase (HPGDS ) transcripts in the pitui-
tary glands of hens with high egg production, laying, and
ovulation rates. The HPGDS gene is highly conserved through
mammals and its encoded protein belongs to the AA meta-
bolism pathway.113 This enzyme catalyzes conversion of the
short-half-life prostaglandin H2 (PGH2) to PGD2 and plays a
role in the production of prostanoids in the immune system
and mast cells.114 PGD2 can be further metabolized to the F
and J series of prostaglandins, including PGJ2.
115
Studies by our group and others indicate that this con-
servation can be further extended to vertebrate species.23
It was previously reported that PGD2 induces LH release
from the rat pituitary gland without modulating hypotha-
lamic GnRH.116 Therefore, a high HPGDS level might
enhance ovulation via a mechanism other than the GnRH-
dependent pathway. In a cellular model using primary cul-
ture of chicken pituitary cells, HPGDS downstream metab-
olites PGD2 and PGJ2 or a PPAR pan agonist, GW9578,
significantly elevate LHB mRNA and protein levels in a dose-
and time-dependent manner; treatment with AA alone
significantly induced 15-d-PGJ2 and LHB mRNA and protein
expression. Furthermore, HPGDS overexpression in these
cells in medium containing AA dramatically increases 15-d-
PGJ2/PGJ2 and LHB mRNA and protein levels. In the pitui-
tary gland of ovulating hens, there are significant correla-
tions between HPGDS and PPARA and between HPGDS and
PPARG mRNA levels. PPARA- and PPARG-specific antagonists
(GW6471 and T0070907, respectively) significantly suppress
endogenous LHB mRNA and protein levels. Moreover, both
antagonists attenuated AA-induced LHB mRNA and HPGDS-
induced (in the presence of AA) LHB mRNA and protein
levels in primary cultures of chicken pituitary cells. Higher
LHBmRNA/LHB protein ratios in PGD2-, PGJ2-, AA-, HPGDS-,
and GW9578-induced and in GW6471- and T0070907-
suppressed pituitary cells suggest that LHB transcription
occurs before translation. Therefore, HPGDS induces LHB
transcription and subsequent translation via the PPAR
signaling pathway in the chicken pituitary cellular model.23
In the AA metabolic pathway, AA is oxidized by consti-
tutive prostaglandin endoperoxide synthase 1 (PTGS1, also
known as cyclooxygenase-1/COX-1) and inducible PTGS2
(also known as COX-2) to yield PGG2, which is in turn
sequentially converted to the di-unsaturated prostaglandins
PGH2 and PGD2 by hydroperoxidase and HPGDS, respec-
tively. PTGS1 or PTGS2 is a rate-limiting enzyme in prosta-
glandin synthesis.117 The final product of this pathway,
PGJ2, is intracellularly converted to albumin-dependent
D12-PGJ2 and nonenzymatically dehydrated 15-d-PGJ2.
114
The natural precursor of PGJ2 derivatives appears to be
PGD2, as its administration leads to a large increase in D
12-
PGJ2 in vivo.
118 Alternatively, 15-d-PGJ2 is capable of being
produced extracellularly via non-enzymatic conversion of
PGD2 and may function as an autocrine and/or paracrine
factor during inflammatory processes.119
Surprisingly, we found that treatments with higher con-
centrations of PGD2, PGJ2, or GW9578 caused reverse effects
on induction of LHB mRNA and protein levels in chicken pri-
mary pituitary cells.23 Prostaglandins belong to a family of
biologically active molecules with a diverse range of actions,depending on the prostaglandin type and cell target. The
prostaglandin 15-d-PGJ2 is a potent anti-inflammatory agent
that represses the expression of a number of inflammatory
response genes, including inducible nitric oxide synthase,
tumor necrosis factor alpha, matrix metallopeptidase 9, and
PTGS2 in activated macrophages. Some of these repressive
actions are mediated by high-affinity binding of 15-d-PGJ2 to
PPARG.120,121 Additional studies have demonstrated that 15-
d-PGJ2 inhibits transcriptional activation by polypeptide
gene enhancer in B-cells 1 (NFKB1, also known as NFkB) and
Jun activation domain-binding protein (JUN, also known as
AP-1) in a PPARG-dependent manner.120 As a transcriptional
factor, NFKB1 protein resides in the cytoplasm in association
with its repressor NFKBIA. Upon cellular signaling, NFKBIA can
be phosphorylated by the conserved helixeloopehelix ubiq-
uitous kinase (CHUK, also known as IkBa kinase), resulting in
release of NFKB1 and its migration to the nucleus. The pros-
taglandin 15-d-PGJ2 inhibits NFKB1, either by hindering
CHUK122,123 or by directly interacting with NFKB1 pro-
tein.120,123 Furthermore, PTGS2 is transactivated by NFKB1
protein124,125 and NFKB1 transcription is inhibited by 15-d-
PGJ2.
126 Taken together with our results, these findings sug-
gest that higher PGD2, PGJ2, and downstream metabolite
levels, as well as the PPAR agonist GW9578, negatively regu-
late PTGS2 expression via a PPAR-dependent pathway,
resulting in suppression of LHB mRNA and protein levels and
thus acting as a negative feedback loop. This might explain
why conditional knockout of Pparg in pituitary gonadotrophs
causedan increase in bloodLH levels in femalemice47 and the
defect in fertility characterized by reduced litter size47 is due
to disruption of the HPG axis.
It was recently revealed that PPARG is abundantly
expressed and is therefore an important novel molecular
target in pituitary adenoma cells, given that the PPARG ligand
rosiglitazone inhibits tumor cell growth and ACTH, GH, PRL,
and LH secretion both in vitro and in vivo.127 In the GH3 rat
pituitary cell line, which synthesizes and secrets acromegalic
GH, treatmentwith the syntheticPPARG ligands ciglitazoneor
rosiglitazone arrests cell proliferation and decreases GH
mRNA levels via binding to PPRE with RXRA in the GH pro-
moter.51 It was also reported that although pioglitazone has a
potency similar to that of rosiglitazone for inhibition of the
proliferation of GH3 (PRL- and GH-releasing) cells, the PPARG
antagonist GW9662 does not lead to significant reversal of the
antiproliferative effect of rosiglitazone; in fact, GW9662
suppresses proliferation by itself.128 Therefore, the anti-
proliferative action of rosiglitazone probably does not occur
via the PPARG pathway. Instead, in the mouse gonado-
tropinoma cell line LbT2, PPAR activation differentially
regulated gonadotrope cell proliferation and gonadotropin
transcription in a ligand-dependent manner, that is, the
PPARA and PPARG ligands fenofibric acid and pioglitazone,
respectively, directly suppressed the transcriptional activ-
ities of FSHB, LHB and GnRHR.129 Our earlier study23 and that
of Takeda et al129 differed in terms of the types and concen-
trations of PPAR ligands used. Besides, because Takeda et al
did not use antagonists, the doses of fenofibric acid or pio-
glitazone they applied may have suppressed LHB transcrip-
tional activities via a PPAR-independent pathway, the
negative feedback loop, or suppression ofGnRHR. In contrast,
we applied PPARA- and PPARG-specific antagonists and found
that both antagonists significantly suppressed endogenous
PPARs in the pituitary gland in female reproduction 7and HPGDS/AA-induced LHB mRNA and protein levels.
GW6471 is a PPARA-specific antagonist that completely in-
hibits GW409544-induced activation of PPARA; it also induces
a PPARA conformation that interacts efficiently with co-re-
pressors.130 T0070907 is a potent and selective antagonist of
the human PPARG receptor that inhibits binding to rosiglita-
zone; T0070907 covalently binds to Cys313 of PPARG and in-
duces conformational changes that block the recruitment of
transcriptional cofactors to the PPARGeRXR heterodimer.131
Our results strongly suggest that in the chicken primary pitu-
itary cell model, both endogenous and HPGDS/AA-induced
LHB mRNA and protein levels are regulated via the PPAR
signaling pathway (Fig. 3).23
To examine whether this is also true for mammals, we
tested rat primary pituitary cells. Quantitative reverse
transcription-polymerase chain reaction and immunoblotting
analysis revealed that Lhb mRNA and protein levels were
significantly upregulated after treatment with GW9578 or
transfection of plasmids carrying human PPARA-turbo GFP
(unpublished data). Further knockdown experiments will
provide more in vitro evidence.Ovary
Our studies revealed significantly higher HPGDS mRNA and
protein levels in ovaries than in testes of adult chickens.23WeCytoplasma
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Figure 3 Peroxisome proliferator-activated receptors (PPARs)
Hypothesis 1, PPARs and retinoid X receptor alpha (RXRA) directly b
and RXRA bind to the LHB enhancer and interact with well-known t
GnRHR and further induce LHB transcription. PGH2, prostaglandin
prostaglandin D2; DP1, prostaglandin D2 receptor (DP); DP2, prosta
PPAR agonist; GW6471, a PPARA-specific antagonist; T0070907, a PP
group A, member 1; PITX1, paired-like homeodomain 1; EGR1, ear
GnRHR, gonadotropin-releasing hormone receptor; PKA, protein kin
alpha; JUN, jun proto-oncogene.also found that all Ppars are expressed in the rat ovary during
follicular development and periovulatory periods,132,133
confirming the presence of a HPGDSePPAR pathway in the
ovary in vertebrates. The presence of active endogenous
PPARG in rat and sheep ovaries was confirmed by an increase
in reporter activity in granulosa cells transiently transfected
with reporter constructs whose expression was driven by
PPREs, in the absence or presence of agonists for
PPARG.52,134 In rat granulosa cells, Pparg also binds to
DNA.134 All these results demonstrate that PPARG is func-
tional in granulosa cells and its endogenous ligand is also
present in these cells.22
In sheep and rats, PPARG is detected early in folliculo-
genesis (at the primary/secondary follicle stage), increases
until the large follicle stage,anddecreasesafter theLHsurge.
Most notably, Pparg expression is primarily limited to gran-
ulosa cells in developing follicles and is downregulated by
LH,52,132 suggesting a similar negative feedback loopbetween
PPAR and LH in the ovary to that observed in pituitary cells.
According to the above findings and evidence from condi-
tional/ovary Ppar knockout mice,92 Pparg potentiallys affect
somatic cell/oocyte communication not only by impacting
granulosa cell development but also via direct effects on
oocytes. In reality, the species and the statusof granulosa cell
differentiation (follicular phase, before or after the gonado-
tropin surge) can modulate the actions of synthetic PPAR
ligands on steroidogenesis.52,132,135e137 For example,Nuclear 
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Other  genes
Hypothesis 3
might transactivate LHB via three hypothetical mechanisms.
ind to the LHB proximal promoter region. Hypothesis 2, PPARs
ranscription factors of LHB. Hypothesis 3, PPARs might regulate
H2; HPGDS, hematopoietic prostaglandin D synthase; PGD2,
glandin D2 receptor 2; PGJ2, prostaglandin J2; GW9578, a pan
ARG-specific antagonist; NR5A1, nuclear receptor subfamily 5,
ly growth response 1; GnRH, gonadotropin-releasing hormone;
ase, cAMP-dependent, catalytic, alpha; PKC, protein kinase C,
8 Y.-L. Shiue et al.treatment with rosiglitazone or pioglitazone stimulated pro-
gesterone secretion by a mixture of human granulosa, theca,
and stroma cells obtained from premenopausal
or perimenopausal patients without gonadotropin treatment
at the time of oophorectomy.138 The effects of PPARs
on steroidogenesis in ovaries have been reviewed
elsewhere.20,22,109Targeting PPARs for female fertility disorders
In addition to the fatty acid metabolic pathway, PPARs have
been associatedwithmany human diseases including obesity,
insulin resistance, type 2 diabetes, atherosclerosis, hyper-
tension, inflammation, and cancer. It has been suggested that
ligands for these receptors have therapeutic potential for
selected human diseases. Synthetic ligands for one family
member, PPARG, are currently widely used as treatment for
chronic diseases such as type 2 diabetes and another condi-
tion in which insulin resistance is a factor (PCOS).Conclusions
PPAR family members play key roles in regulating energy
homeostasis, particularly fatty acid oxidation and carbo-
hydrate metabolism. An increasing body of in vivo and
in vitro research has recently revealed that PPARs also have
functions in reproductive organs including the HPG axis and
the placenta during pregnancy in several species. These
studies strongly suggest that PPARs might play critical roles
in reproduction and development, in addition to their
central actions in energy homeostasis. The exact mecha-
nism by which PPARs regulate LHB transcription remains to
be elucidated. However, in the near future, natural or
synthetic ligands of PPARs might be used in a broad spec-
trum of reproduction treatments such as improvement of
follicular development and ovulation, infertility associated
with metabolism disorders, regulation of steroidogenesis,
certain complications of pregnancy, and sex-hormone-
sensitive cancers affecting reproductive tissues, such as
breast, ovary, and pituitary adenomas.References
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